1. Home
  2. ELMD vs TGTX Comparison

ELMD vs TGTX Comparison

Compare ELMD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electromed Inc.

ELMD

Electromed Inc.

HOLD

Current Price

$28.26

Market Cap

238.7M

Sector

Health Care

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.75

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELMD
TGTX
Founded
1992
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.7M
5.5B
IPO Year
2010
1995

Fundamental Metrics

Financial Performance
Metric
ELMD
TGTX
Price
$28.26
$30.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$36.00
$54.75
AVG Volume (30 Days)
50.3K
1.4M
Earning Date
02-10-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
30.89
N/A
EPS
0.94
2.78
Revenue
$66,218,999.00
$531,898,000.00
Revenue This Year
$14.63
$87.88
Revenue Next Year
$11.54
$48.75
P/E Ratio
$30.56
$11.19
Revenue Growth
16.05
100.88
52 Week Low
$17.73
$25.28
52 Week High
$35.56
$46.48

Technical Indicators

Market Signals
Indicator
ELMD
TGTX
Relative Strength Index (RSI) 54.77 46.01
Support Level $26.98 $29.79
Resistance Level $30.47 $31.37
Average True Range (ATR) 1.25 1.00
MACD -0.23 0.04
Stochastic Oscillator 43.59 45.68

Price Performance

Historical Comparison
ELMD
TGTX

About ELMD Electromed Inc.

Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: